资料显示，深圳迈瑞生物医疗电子股份有限公司位于广东省深圳市南山区高新技术产业园区科技南十二 路迈瑞大厦1-4层，成立日期1999年1月25日，上市日期2018年10月16日，公司主营业务涉及医疗器械的 研发、制造、营销及服务。主营业务收入构成为：体外诊断类产品38.37%，生命信息与支持类产品 32.73%，医学影像类产品19.78%，电生理与血管介入类产品7.25%，其他产品1.56%，其他(补 充)0.31%。 迈瑞医疗所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：血氧仪、智慧医疗、体 外诊断、医疗器械、融资融券等。 10月10日，迈瑞医疗盘中下跌2.00%，截至10:59，报243.27元/股，成交9.22亿元，换手率0.31%，总市 值2949.51亿元。 资金流向方面，主力资金净流入2472.10万元，特大单买入1.11亿元，占比12.00%，卖出1.02亿元，占比 11.11%；大单买入2.46亿元，占比26.69%，卖出2.30亿元，占比24.90%。 迈瑞医疗今年以来股价跌3.36%，近5个交易日跌0.71%，近20日涨4.77%，近60日涨11.93%。 分红方面，迈瑞医疗 ...

资金流向方面，主力资金净流入298.89万元，大单买入707.65万元，占比16.08%，卖出408.75万元，占 比9.29%。 康泰医学今年以来股价涨21.69%，近5个交易日涨2.27%，近20日涨1.22%，近60日涨11.81%。 今年以来康泰医学已经1次登上龙虎榜，最近一次登上龙虎榜为7月25日，当日龙虎榜净买入6861.01万 元；买入总计1.50亿元 ，占总成交额比27.22%；卖出总计8151.24万元 ，占总成交额比14.78%。 资料显示，康泰医学系统(秦皇岛)股份有限公司位于河北省秦皇岛市经济技术开发区秦皇西街112号， 成立日期1996年7月9日，上市日期2020年8月24日，公司主营业务涉及从事医疗诊断、监护设备的研 发、生产和销售。主营业务收入构成为：院线类产品47.54%，家用类产品41.01%，其他产品11.45%。 10月10日，康泰医学盘中上涨2.15%，截至10:38，报16.66元/股，成交4400.49万元，换手率1.06%，总 市值66.94亿元。 康泰医学所属申万行业为：医药生物-医疗器械-医疗设备。所属概念板块包括：互联医疗、体外诊断、 抗原检测、幽门螺杆概念 ...

9月30日，迈瑞医疗盘中上涨2.03%，截至13:31，报243.86元/股，成交12.31亿元，换手率0.42%，总市 值2956.66亿元。 资金流向方面，主力资金净流出442.85万元，特大单买入1.61亿元，占比13.07%，卖出1.62亿元，占比 13.20%；大单买入3.20亿元，占比26.01%，卖出3.23亿元，占比26.24%。 机构持仓方面，截止2025年6月30日，迈瑞医疗十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1.31亿股，相比上期减少302.52万股。易方达创业板ETF（159915）位居第五大流通股 东，持股1365.26万股，相比上期减少3.01万股。华宝中证医疗ETF（512170）位居第六大流通股东，持 股1101.24万股，相比上期增加88.93万股。华泰柏瑞沪深300ETF（510300）位居第七大流通股东，持股 1081.65万股，相比上期增加88.31万股。易方达沪深300医药ETF（512010）位居第八大流通股东，持股 996.89万股，相比上期减少75.63万股。景顺长城新兴成长混合A（260108）位居第九大流通股东，持股 800.00万 ...

截至6月30日，迈瑞医疗股东户数9.16万，较上期减少0.68%；人均流通股13241股，较上期增加0.69%。 2025年1月-6月，迈瑞医疗实现营业收入167.43亿元，同比减少18.45%；归母净利润50.69亿元，同比减 少32.96%。 分红方面，迈瑞医疗A股上市后累计派现336.99亿元。近三年，累计派现233.88亿元。 机构持仓方面，截止2025年6月30日，迈瑞医疗十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1.31亿股，相比上期减少302.52万股。易方达创业板ETF（159915）位居第五大流通股 东，持股1365.26万股，相比上期减少3.01万股。华宝中证医疗ETF（512170）位居第六大流通股东，持 股1101.24万股，相比上期增加88.93万股。华泰柏瑞沪深300ETF（510300）位居第七大流通股东，持股 1081.65万股，相比上期增加88.31万股。易方达沪深300医药ETF（512010）位居第八大流通股东，持股 996.89万股，相比上期减少75.63万股。景顺长城新兴成长混合A（260108）位居第九大流通股东，持股 800.00万股，持股数量 ...

Core Viewpoint - Lepu Medical experienced a stock price decline of 2.08% on September 26, with a trading price of 17.42 yuan per share and a total market capitalization of 32.76 billion yuan [1] Financial Performance - Lepu Medical's revenue for the first half of 2025 was 3.369 billion yuan, a year-on-year decrease of 0.43%, while the net profit attributable to shareholders was 691 million yuan, down 0.91% year-on-year [2] - The company has cumulatively distributed 4.957 billion yuan in dividends since its A-share listing, with 2.058 billion yuan distributed in the last three years [3] Stock Market Activity - The stock price of Lepu Medical has increased by 57.68% year-to-date, but it has seen a decline of 4.96% in the last five trading days and 7.59% over the past 20 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with a net buy of 29.5585 million yuan on June 4 [1] Shareholder Structure - As of June 30, 2025, Lepu Medical had 100,100 shareholders, an increase of 6.18% from the previous period, with an average of 16,152 circulating shares per shareholder, down 5.82% [2] - Major shareholders include Huabao Zhongzheng Medical ETF and E Fund Growth Enterprise ETF, with changes in their holdings noted [3]

9月25日，迈瑞医疗盘中上涨2.01%，截至11:20，报238.60元/股，成交12.90亿元，换手率0.45%，总市 值2892.89亿元。 截至6月30日，迈瑞医疗股东户数9.16万，较上期减少0.68%；人均流通股13241股，较上期增加0.69%。 2025年1月-6月，迈瑞医疗实现营业收入167.43亿元，同比减少18.45%；归母净利润50.69亿元，同比减 少32.96%。 分红方面，迈瑞医疗A股上市后累计派现336.99亿元。近三年，累计派现233.88亿元。 机构持仓方面，截止2025年6月30日，迈瑞医疗十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1.31亿股，相比上期减少302.52万股。易方达创业板ETF（159915）位居第五大流通股 东，持股1365.26万股，相比上期减少3.01万股。华宝中证医疗ETF（512170）位居第六大流通股东，持 股1101.24万股，相比上期增加88.93万股。华泰柏瑞沪深300ETF（510300）位居第七大流通股东，持股 1081.65万股，相比上期增加88.31万股。易方达沪深300医药ETF（512010）位居第八大流通股 ...

Core Viewpoint - Baolait's stock price has shown a year-to-date increase of 29.59%, despite recent declines in the last five and twenty trading days, indicating volatility in its performance [2]. Company Overview - Baolait Medical Technology Co., Ltd. was established on June 28, 1993, and listed on July 19, 2011. The company is located in Zhuhai, Guangdong Province, and specializes in the research, production, sales, and service of medical device products [2]. - The main revenue composition of Baolait includes hemodialysis products (77.51%), monitoring devices (21.39%), and other products (1.10%) [2]. Financial Performance - For the first half of 2025, Baolait reported operating revenue of 523 million yuan, a year-on-year decrease of 2.43%. However, the net profit attributable to shareholders increased by 152.22% to 1.3134 million yuan [2]. - As of June 30, 2025, Baolait has distributed a total of 244 million yuan in dividends since its A-share listing, with 35.1578 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, Baolait had 18,400 shareholders, a decrease of 6.12% from the previous period. The average circulating shares per person increased by 6.50% to 11,477 shares [2]. - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund increased its holdings by 259,800 shares, while Hua Xia Zhong Zheng 500 Index Enhanced A became a new shareholder with 1,228,900 shares [3]. Market Activity - On September 24, Baolait's stock price rose by 2.03% to 8.54 yuan per share, with a trading volume of 21.1786 million yuan and a turnover rate of 1.19%. The total market capitalization reached 2.259 billion yuan [1]. - The net inflow of main funds was 1.2812 million yuan, with large single purchases accounting for 10.99% of the total, while sales accounted for 4.94% [1].

Core Viewpoint - Aipeng Medical's stock price has shown significant volatility, with a year-to-date increase of 77.97% but a recent decline in the last 20 days by 7.71% [2] Group 1: Stock Performance - On September 17, Aipeng Medical's stock fell by 2.04%, trading at 31.26 CNY per share with a total transaction volume of 1.49 billion CNY and a market capitalization of 39.40 billion CNY [1] - The stock has experienced a 3.61% increase over the last five trading days and a 5.50% increase over the last 60 days [2] Group 2: Financial Performance - For the first half of 2025, Aipeng Medical reported a revenue of 1.59 billion CNY, a year-on-year decrease of 11.31%, and a net profit attributable to shareholders of -19.38 million CNY, a decrease of 317.90% [2] - Cumulative cash dividends since the company's A-share listing amount to 113 million CNY, with 16.39 million CNY distributed over the past three years [3] Group 3: Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased by 57.18% to 32,400, while the average circulating shares per person decreased by 36.33% to 2,711 shares [2] - Aipeng Medical has appeared on the trading leaderboard six times this year, with the most recent instance on August 8, where net purchases amounted to 11.92 million CNY [2]

Company Overview - Guoxing Optoelectronics Co., Ltd. is located in Foshan, Guangdong Province, established on August 31, 1981, and listed on July 16, 2010. The company specializes in the research, production, and sales of LED devices and components [2] - The revenue composition of Guoxing Optoelectronics includes: 69.80% from LED packaging and component products, 17.41% from trade and application products, 5.55% from other sources, 4.12% from integrated circuit packaging and testing, and 3.11% from epitaxial and chip products [2] - The company belongs to the electronic-optical optoelectronics-LED industry and is associated with concepts such as small-cap, blood oxygen monitors, massive transfer concepts, ultra-high definition, and gallium nitride [2] Financial Performance - As of September 10, 2023, the number of shareholders of Guoxing Optoelectronics is 71,600, a decrease of 3.33% from the previous period, with an average of 8,643 circulating shares per person, an increase of 3.45% [2] - For the first half of 2025, Guoxing Optoelectronics achieved operating revenue of 1.681 billion yuan, a year-on-year decrease of 9.30%, and a net profit attributable to the parent company of 24.57 million yuan, a year-on-year decrease of 56.31% [2] Stock Performance - On September 16, 2023, Guoxing Optoelectronics' stock price increased by 2.08%, reaching 9.31 yuan per share, with a trading volume of 99.32 million yuan and a turnover rate of 1.75%, resulting in a total market value of 5.758 billion yuan [1] - The stock has decreased by 31.39% year-to-date, with a 1.97% increase over the last five trading days, a 6.99% decrease over the last 20 days, and an 8.00% decrease over the last 60 days [1] - Guoxing Optoelectronics has appeared on the "Dragon and Tiger List" nine times this year, with the most recent appearance on January 14, 2023, where the net buying on that day was -44.12 million yuan, with total buying of 165 million yuan (7.66% of total trading volume) and total selling of 209 million yuan (9.71% of total trading volume) [1] Dividend Information - Since its A-share listing, Guoxing Optoelectronics has distributed a total of 1.135 billion yuan in dividends, with 105 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited is the sixth-largest circulating shareholder of Guoxing Optoelectronics, holding 3.3582 million shares, a decrease of 3.8195 million shares compared to the previous period [3]

Company Overview - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. was established on January 25, 1999, and listed on October 16, 2018. The company is located in the High-tech Industrial Park, Nanshan District, Shenzhen, Guangdong Province. Its main business involves the research, manufacturing, marketing, and service of medical devices [1]. Financial Performance - As of June 30, 2025, Mindray Medical reported a revenue of 16.743 billion yuan, a year-on-year decrease of 18.45%. The net profit attributable to shareholders was 5.069 billion yuan, down 32.96% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 33.699 billion yuan, with 23.388 billion yuan distributed in the last three years [3]. Stock Market Activity - On September 4, 2023, Mindray Medical's stock price fell by 2.05%, closing at 233.92 yuan per share, with a trading volume of 1.417 billion yuan and a turnover rate of 0.49%. The total market capitalization was 283.614 billion yuan [1]. - Year-to-date, the stock price has decreased by 7.55%, with a 5-day decline of 5.33%, a 20-day increase of 1.36%, and a 60-day decrease of 1.13% [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders was 91,600, a decrease of 0.68% from the previous period. The average number of circulating shares per person increased by 0.69% to 13,241 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 131 million shares (a decrease of 3.0252 million shares), and E Fund's various ETFs, with mixed changes in holdings [3]. Business Segmentation - The revenue composition of Mindray Medical includes: in vitro diagnostic products (38.37%), life information and support products (32.73%), medical imaging products (19.78%), electrophysiology and vascular intervention products (7.25%), and other products (1.56%) [1].